Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years

Leora R. Feldstein; Amadea Britton; Lauren Grant; Ryan E. Wiegand; Jasmine Ruffin; Tara M Babu; Melissa Briggs Hagen; Jefferey L. Burgess; Alberto J. Caban‐Martinez; Helen Y. Chu; Katherine Ellingson; Janet A. Englund; Kurt T. Hegmann; Zuha Jeddy; Adam S. Lauring; Karen Lutrick; Emily T. Martin; Clare Mathenge; Jennifer K. Meece; Claire M. Midgley; Arnold S. Monto; Gabriella Newes‐Adeyi; Leah Odame‐Bamfo; Lauren E.W. Olsho; Andrew L. Phillips; P. Ramona; Sharon Saydah; Ning Smith; Laura C. Steinhardt; Harmony L. Tyner; Meredith Vandermeer; Molly Vaughan; Sarang K. Yoon; Manjusha Gaglani; Allison L. Naleway

doi:10.1001/jama.2023.27022

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The bivalent COVID-19 vaccines protected children and adolescents against SARS-CoV-2 infection and symptomatic COVID-19. These data demonstrate the benefit of COVID-19 vaccine in children and adolescents. All eligible children and adolescents should remain up to date with recommended COVID-19 vaccinations.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Feldstein et al. (2024) studied this question.

synapsesocial.com/papers/69d747718e958094d1b8aac2 https://doi.org/10.1001/jama.2023.27022

View Full Paper

Ask AI

Bookmark

Share

Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years

Ask about this paper

Abstract

Discussion

Cite This Study

Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading